Clinical Trial Update: Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating the efficacy and safety of Biphasic Insulin Aspart 30 FlexPen in insulin-naive adults with Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Biphasic Insulin Aspart 30 FlexPen (biphasic insulin aspart 30)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED